v3.26.1
CONSOLIDATED SCHEDULE OF INVESTMENTS (Parentheticals) 1
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
investment
Dec. 31, 2025
USD ($)
investment
Percent of net assets 223.84% [1],[2] 221.58% [3],[4]
Investment, tax basis, unrealized gain $ 74,800 $ 68,000
Investment, tax basis, unrealized loss 96,200 86,700
Investment, tax basis, unrealized loss 21,400 18,700
Tax basis of investments, cost for income tax purposes 807,000 802,300
Investment company debt security, nonaccrual 38,600 39,700
Investment company debt security, nonaccrual, fair value 16,100 17,100
Total portfolio company investments $ 785,635 [1],[5],[6] $ 783,544 [3],[7],[8]
Basis spread on variable rate 3.67% 3.82%
Net change in unrealized gains (losses) on investments $ (2,663)  
Net realized gains (losses) on investments $ (299)  
Interest rate 13.50%  
Non-Qualifying Assets    
Percent of net assets 29.80% 28.40%
Investments Not Valued At Fair Value    
Number of investments | investment 5 4
Investments Restricted On Sales    
Percent of net assets 223.60% 221.40%
Total portfolio company investments $ 784,800 $ 782,900
Affiliate Investment    
Net change in unrealized gains (losses) on investments $ 300 1,700
Net realized gains (losses) on investments   $ 5,800
Hybrid Equity Investment    
Interest rate 16.00% 16.00%
Debt Investments    
Basis spread on variable rate 6.75%  
Interest rate   3.25%
Investment, variable interest rate, type flag Prime Rate [Member]  
Debt Investments Floating Interest Rate    
Percent of net assets 63.80% 63.00%
Interest rate 3.25%  
Outstanding principal $ 433,500 $ 426,300
[1] Non-income producing investments.
[2] Value as a percentage of net assets.
[3] Non-income producing investments.
[4] Value as a percentage of net assets.
[5] The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). Unless otherwise indicated, all of the Company’s portfolio company investments are subject to restrictions on sales. As of March 31, 2026, the Company’s portfolio company investments that were subject to restrictions on sales totaled $784.8 million at fair value and represented 223.6% of the Company’s net assets. In addition, unless otherwise indicated, as of March 31, 2026, all investments are pledged as collateral as part of the Company’s revolving credit facility.
[6] Except for equity in five public companies, all investments were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s board of directors (the “Board”).
[7] The Company generally acquires its investments in private transactions exempt from registration under the Securities Act. Unless otherwise indicated, all of the Company’s portfolio company investments are subject to restrictions on sales. As of December 31, 2025, the Company’s portfolio company investments that were subject to restrictions on sales totaled $782.9 million at fair value and represented 221.4% of the Company’s net assets. In addition, unless otherwise indicated, as of December 31, 2025, all investments are pledged as collateral as part of the Company’s revolving credit facility.
[8] Except for equity in four public companies, all investments were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Board.